NeRRe Therapeutics ^Companies

NeRRe Therapeutics is a biotechnology company based in Stevenage, United Kingdom. They specialize in developing clinical and pre-clinical neurokinin receptor antagonists. Their main goal is to develop breakthrough treatments for cough hypersensitivity disorders, particularly chronic cough caused by idiopathic pulmonary fibrosis (IPF). They have demonstrated proof of efficacy in patients with refractory or unexplained cough and are working towards finding a solution for this unmet medical need. Led by CEO Mary Kerr, the company's achievements include the successful sale of sister company KaNDy Therapeutics to Bayer in 2020 for $425 million.